Breakthrough magneto-plasmonic imaging technology
The EU-funded SWIMMOT project will establish the scientific and technological basis for radically new in vivo molecular imaging based on a switchable contrast agent (CA) and corresponding optical imaging technology. The CA will be based on novel magnetic core/ plasmonic gold shell nanorods with engineered biofunctional shells. The magneto-plasmonic imaging will switch the CA on and off, resulting in complete removal of the imaging background. This discrimination of the background from the CA signal will yield ultra-high contrast molecular imaging. The technology will enable the in vivo visualisation and quantification of soluble biomarkers at cellular level resolution, surpassing all current capabilities. Developers plan to apply the technology to diabetes research and demonstrate its potential in the zebrafish model.
Call for proposal
See other projects for this call